Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRR | Q9GZT4 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 10/20 | 0.47 |
| ▸ | PPARA | Q07869 | 10/20 | 0.47 |
| ▸ | PPARD | Q03181 | 4/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.44 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757308 | 1.00 | SRR (0.53) | SRRFFAR1PPARGPPARAPPARD | |
| SCHEMBL1094835 | 1.00 | SRR (0.53) | SRRFFAR1PPARGPPARAPPARD | |
| SCHEMBL15679980 | 1.00 | SRR (0.53) | SRRFFAR1PPARGPPARAPPARD | |
| SCHEMBL756254 | 0.85 | PPARG (0.57) | PPARGPPARAPPARD | |
| SCHEMBL28748038 | 0.85 | SRR (0.47) | SRRPPARGPPARASLC7A5 | |
| SCHEMBL1105056 | 0.84 | MAOB (0.46) | SRRSLC7A5MAOAMAOB | |
| SCHEMBL5383259 | 0.83 | SRR (0.50) | SRRFFAR1PPARGPPARAPPARD | |
| SCHEMBL31321016 | 0.83 | PPARG (0.56) | SRRFFAR1PPARGPPARAPPARD | |
| SCHEMBL22264856 | 0.83 | PPARG (0.56) | SRRFFAR1PPARGPPARAPPARD | |
| SCHEMBL22264858 | 0.83 | PPARG (0.56) | SRRFFAR1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12291494-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2025-05-06 | — | — | US | disclosed |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2024-08-22 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| EP-3628317-A1 | METHODS OF TREATING FIBROSIS | Nogra Pharma Limited (IE) | 2020-04-01 | — | — | EP | disclosed |
| EP-2811993-B1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LTD (IE) | 2019-10-09 | — | — | EP | disclosed |
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | NOGRA PHARMA LIMITED (IE) | 2018-07-10 | — | — | US | disclosed |
| EP-2895160-B1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2018-05-30 | — | — | EP | disclosed |
| EP-2355809-A1 | METHODS FOR PREVENTING OR REDUCING COLON CARCINOGENESIS | Giuliani International Limited (IE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2355810-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | Giuliani International Limited (IE) | 2011-08-17 | — | — | EP | disclosed |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | NOGRA PHARMA LIMITED (IE) | 2011-06-23 | — | — | US | disclosed |
| WO-2010063472-A1 | METHODS FOR PREVENTING OR REDUCING COLON CARCINOGENESIS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010063470-A2 | METHODS FOR PREVENTING OR REDUCING CARCINOGENESIS OR OXIDATIVE STRESS | GIULIANI INTERNATIONAL LIMITED (IE) | 2010-06-10 | — | — | WO | disclosed |
| EP-2131829-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | Giuliani International Limited (IE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | NOGRA PHARMA LIMITED (IE) | 2009-02-19 | — | — | US | disclosed |
| WO-2008104557-A1 | PPAR-GAMMA AGONISTS FOR THE INDUCTION OF CATIONIC ANTIMICROBIAL PEPTIDE EXPRESSION AS IMMUNOPROTECTIVE STIMULANTS | GIULIANI INTERNATIONAL LIMITED (IE) | 2008-09-04 | — | — | WO | disclosed |
| EP-1910270-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | Giuliani International Limited (IE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010516-A2 | COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD | GIULIANI INTERNATIONAL LIMITED (IE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016381-B2 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field | EGFR, ERBB3, FGFR3 | SRR 1855/4885FFAR1 55/4885PPARG 4/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | SRR 3600/4885FFAR1 2768/4885PPARG 669/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | SRR 1482/4885FFAR1 946/4885PPARG 69/4885 |
| US-20240279157-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | SRR 3600/4885FFAR1 2768/4885PPARG 669/4885 |
| US-20090048343-A1 | Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field | EGFR, ERBB3, FGFR3 | SRR 1855/4885FFAR1 55/4885PPARG 4/4885 |
| US-12291494-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | SRR 3600/4885FFAR1 2768/4885PPARG 669/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | SRR 3600/4885FFAR1 2768/4885PPARG 669/4885 |
| US-20110152225-A1 | PPAR-Gamma Agonists for the Induction of Cationic Antimicrobial Peptide Expression as Immunoprotective Stimulants | PPARG, FABP2, PPARD | SRR 1693/4885FFAR1 87/4885PPARG 1/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | SRR 3600/4885FFAR1 2768/4885PPARG 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.